TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 285 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q1 2022. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,858 | -11.6% | 2,124 | -10.2% | 0.00% | 0.0% |
| Q2 2023 | $37,170 | +78985.1% | 2,366 | -16.6% | 0.00% | 0.0% |
| Q1 2023 | $47 | +30.6% | 2,836 | +22.8% | 0.00% | 0.0% |
| Q4 2022 | $36 | -100.0% | 2,309 | -80.7% | 0.00% | -75.0% |
| Q2 2022 | $168,000 | +211.1% | 11,938 | +218.0% | 0.00% | +300.0% |
| Q1 2022 | $54,000 | -68.4% | 3,754 | -63.1% | 0.00% | -75.0% |
| Q2 2021 | $171,000 | -61.0% | 10,165 | -57.6% | 0.00% | -42.9% |
| Q1 2021 | $438,000 | +10850.0% | 23,975 | +11887.5% | 0.01% | – |
| Q4 2020 | $4,000 | -66.7% | 200 | -69.2% | 0.00% | – |
| Q3 2020 | $12,000 | -72.7% | 650 | -73.4% | 0.00% | -100.0% |
| Q2 2020 | $44,000 | – | 2,442 | +16180.0% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 15 | -99.9% | 0.00% | -100.0% |
| Q4 2019 | $205,000 | +502.9% | 10,411 | +448.5% | 0.02% | +750.0% |
| Q2 2019 | $34,000 | +3300.0% | 1,898 | +4645.0% | 0.00% | – |
| Q1 2019 | $1,000 | – | 40 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Adelphi Capital LLP | 8,958,784 | $176,757,000 | 33.75% |
| Ovata Capital Management Ltd | 879,800 | $17,557,092,000 | 13.04% |
| Paulson & Co. | 13,244,711 | $261,318,000 | 5.64% |
| Glenview Capital Management | 30,582,721 | $603,397,000 | 5.28% |
| MIC CAPITAL PARTNERS (PUBLIC) (US) IM, LLC | 718,028 | $14,167,000 | 4.85% |
| Velanne Asset Management Ltd | 302,694 | $5,972,000 | 3.52% |
| Blackcrane Capital, LLC | 172,708 | $3,408,000 | 2.72% |
| Melqart Asset Management (UK) Ltd | 1,557,000 | $30,720,000 | 2.57% |
| GMT CAPITAL CORP | 3,345,976 | $66,016,000 | 2.55% |
| REDWOOD CAPITAL MANAGEMENT, LLC | 827,955 | $16,336,000 | 2.24% |